Galunisertib Drives Treg Fragility and Promotes Dendritic Cell-Mediated Immunity against Experimental Lymphoma

Galunisertib (LY2157299) is a selective ATP-mimetic inhibitor of TGF-β receptor-I activation, currently under clinical trial in a variety of cancers. We have tested the combined effects of galunisertib- and interleukin-15-activated dendritic cells in an aggressive and highly metastatic murine lympho...

Descripción completa

Detalles Bibliográficos
Autores principales: Hira, Sumit Kumar, Rej, Abhinandan, Paladhi, Ankush, Singh, Ranjeet, Saha, Jayasree, Mondal, Indrani, Bhattacharyya, Sankar, Manna, Partha Pratim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7559877/
https://www.ncbi.nlm.nih.gov/pubmed/33089111
http://dx.doi.org/10.1016/j.isci.2020.101623

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7559877/
https://www.ncbi.nlm.nih.gov/pubmed/33089111
http://dx.doi.org/10.1016/j.isci.2020.101623

Ejemplares similares